Arena Pharmaceuticals Inc.

99.9900.00Vol -1Y Perf -
Mar 10th, 2022 16:00 DELAYED
BID0.00 ASK0.00
Open0.00 Previous Close99.99
Pre-Market- After-Market-
 - -  - -%
Target Price
93.88 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
★★ —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★+ —    -
Insiders Value % 3/6/12 mo.
-/-/-82 
Growth Ranking
★★ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-79 
Income Ranking
 —    -
Price Range Ratio 52W %
0.00 
Earnings Rating
Neutral
Market Cap6.17B 
Earnings Date
4th May 2022
Alpha0.04 Standard Deviation0.15
Beta0.54 

Today's Price Range

0.000.00

52W Range

45.50100.00

5 Year PE Ratio Range

-56.5011.70

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-
1 Month
-
3 Months
-
6 Months
7.01%
1 Year
-
3 Years
84.82%
5 Years
382.34%
10 Years
35.86%

TickerPriceChg.Chg.%
ARNA99.990.00000.00
AAPL164.920.05000.03
GOOG117.50-0.6400-0.54
MSFT282.301.98000.71
XOM90.591.64001.84
WFC43.400.21000.49
JNJ170.18-0.0200-0.01
FB196.640.99000.51
GE74.93-0.2500-0.33
JPM115.381.03000.90
 
ProfitabilityValueIndustryS&P 500US Markets
-
-1 133 840.00
-1 126 670.00
-83 240.20
47.34
RevenueValueIndustryS&P 500US Markets
54.00K
0.00
-92.00
-74.26
Earnings HistoryEstimateReportedSurprise %
Q04 2021-2.41-2.54-5.39
Q03 2021-2.42-3.21-32.64
Q02 2021-2.21-2.40-8.60
Q01 2021-2.19-1.989.59
Q04 2020-1.97-2.10-6.60
Q03 2020-1.92-1.6911.98
Q02 2020-2.08-1.6122.60
Q01 2020-2.26-2.0011.50
Earnings Per EndEstimateRevision %Trend
3/2022 QR-2.320.43Positive
6/2022 QR-2.350.84Positive
12/2022 FY-8.32-4.92Negative
12/2023 FY-6.780.44Positive
Next Report Date-
Estimated EPS Next Report-2.32
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume0
Shares Outstanding61.66K
Shares Float61.55M
Trades Count0
Dollar Volume0
Avg. Volume0
Avg. Weekly Volume0
Avg. Monthly Volume0
Avg. Quarterly Volume0

Arena Pharmaceuticals Inc. (NASDAQ: ARNA) stock closed at 99.99 per share at the end of the most recent trading day (a 0.06% change compared to the prior day closing price) with a volume of 5.72M shares and market capitalization of 6.17B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 363 people. Arena Pharmaceuticals Inc. CEO is Amit D. Munshi.

The one-year performance of Arena Pharmaceuticals Inc. stock is %, while year-to-date (YTD) performance is 7.59%. ARNA stock has a five-year performance of 382.34%. Its 52-week range is between 45.5 and 100, which gives ARNA stock a 52-week price range ratio of %

Arena Pharmaceuticals Inc. currently has a PE ratio of -9.90, a price-to-book (PB) ratio of 9.16, a price-to-sale (PS) ratio of 114 173.00, a price to cashflow ratio of 4.50, a PEG ratio of 2.32, a ROA of -62.41%, a ROC of -66.69% and a ROE of -70.30%. The company’s profit margin is 47.34%, its EBITDA margin is -1 126 670.00%, and its revenue ttm is $54.00 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from Arena Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-2.32 for the next earnings report. Arena Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Arena Pharmaceuticals Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Arena Pharmaceuticals Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Arena Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Arena Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.79, ATR14 : 0.38, CCI20 : 42.00, Chaikin Money Flow : 0.34, MACD : 1.37, Money Flow Index : 0.00, ROC : 0.00, RSI : 78.90, STOCH (14,3) : 66.67, STOCH RSI : 1.00, UO : 66.99, Williams %R : -33.33), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Arena Pharmaceuticals Inc. in the last 12-months were: Amit D. Munshi (Buy at a value of $103 325)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (20.00 %)
2 (20.00 %)
7 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
8 (80.00 %)
8 (80.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary Rating-
0.00
-
0.00
-
0.00

Arena Pharmaceuticals Inc.

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

CEO: Amit D. Munshi

Telephone: +1 858 453-7200

Address: 6154 Nancy Ridge Drive, San Diego 92121, CA, US

Number of employees: 363

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

65%35%

Bearish Bullish

71%29%

Bearish Bullish

62%38%


News

Stocktwits